Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Acute intermittent porphyria (AIP) is an inherited disorder of haem metabolism characterized by life‐threatening acute neurovisceral attacks due to the induction of hepatic δ‐aminolevulinic acid synthase 1 (ALAS 1) associated with hydroxymethylbilane synthase (HMBS) deficiency. So far, the treatment of choice is hemin which represses ALAS 1. The main issue in the medical care of AIP patients is the occurrence of debilitating recurrent attacks. Objective: The aim of this study was to determine whether chronic hemin administration contributes to the recurrence of acute attacks. Methods: A follow‐up study was conducted between 1974 and 2015 and included 602 French AIP patients, of whom 46 had recurrent AIP. Moreover, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of Hmbs−/− mice chronically treated by hemin and extended the investigations to five explanted livers from recurrent AIP patients. Results: The introduction of hemin into the pharmacopeia has coincided with a 4.4‐fold increase in the prevalence of chronic patients. Moreover, we showed that both in animal model and in human liver, frequent hemin infusions generate a chronic inflammatory hepatic disease which induces HO 1 remotely to hemin treatment and maintains a high ALAS 1 level responsible for recurrence. Conclusion: Altogether, this study has important impacts on AIP care underlying that hemin needs to be restricted to severe neurovisceral crisis and suggests that alternative treatment targeting the liver such as ALAS 1 and HO 1 inhibitors, and anti‐inflammatory therapies should be considered in patients with recurrent AIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice
Lee, T.-S., & Chau, L.-Y. (2002) · Nature Medicine · doi:10.1038/nm0302-240 · Cited by 1,019
Hemoprotein Bach1 regulates enhancer availability of heme oxygenase‐1 gene
Sun, J., Hoshino, H., Takaku, K., Nakajima, O., Muto, A., Suzuki, H., Tashiro, S., Takahashi, S., Shibahara, S., Alam, J., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf516 · Cited by 637
Characterization of Heme as Activator of Toll-like Receptor 4
Figueiredo, R. T., Fernandez, P. L., Mourao-Sa, D. S., Porto, B. N., Dutra, F. F., Alves, L. S., Oliveira, M. F., Oliveira, P. L., Graça-Souza, A. V., & Bozza, M. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610737200 · Cited by 576
Kautz, L., Meynard, D., Monnier, A., Darnaud, V., Bouvet, R., Wang, R.-H., Deng, C., Vaulont, S., Mosser, J., Coppin, H., et al. (2008) · Blood · doi:10.1182/blood-2008-03-143354 · Cited by 437
Duvigneau, J. C., Piskernik, C., Haindl, S., Kloesch, B., Hartl, R. T., Hüttemann, M., Lee, I., Ebel, T., Moldzio, R., Gemeiner, M., et al. (2008) · Laboratory Investigation · doi:10.1038/labinvest.3700691 · Cited by 101
Dietary iron loading negatively affects liver mitochondrial function
Volani, C., Doerrier, C., Demetz, E., Haschka, D., Paglia, G., Lavdas, A. A., Gnaiger, E., & Weiss, G. (2017) · Metallomics · doi:10.1039/c7mt00177k · Cited by 59
Cited by
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Self-citationScott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Self-citationSystemic messenger RNA as an etiological treatment for acute intermittent porphyria
Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., Benenato, K. E., Burke, K., Santamaría, E., Alegre, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0199-z · Cited by 181
Clinical guide and update on porphyrias
Stölzel, U., Doss, M. O., & Schuppan, D. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.050 · Cited by 175
Metadata
- Authors
- Schmitt, C., Lenglet, H., Yu, A., Delaby, C., Benecke, A., Lefebvre, T., Letteron, P., Paradis, V., Wahlin, S., Sandberg, S., Harper, P., Sardh, E., Sandvik, A. K., Hov, J. R., Aarsand, A. K., Chiche, L., Bazille, C., Scoazec, J. ‐., To-Figueras, J., Carrascal, M., Abian, J., Mirmiran, A., Karim, Z., Deybach, J. ‐., Puy, H., Peoc'h, K., Manceau, H., & Gouya, L.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2018-03-26
- Volume
- 284
- Issue
- 1
- Pages
- 78-91
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2790744750
- Cited by
- 121
- References
- 6
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.